{
    "info": {
        "nct_id": "NCT06072781",
        "official_title": "A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)",
        "inclusion_criteria": "Patients may be eligible for inclusion in the study if they meet the following criteria:\n\n1. Histologically proven LGSOC (ovarian, fallopian, peritoneal)\n2. Documented mutational status of KRAS by a validated tumor-tissue based diagnostic test.\n3. Suitable for treatment with at least one of the Investigator's Choice of Treatments:pegylated liposomal doxorubicin, paclitaxel, letrozole, anastrozole.\n4. Progression or recurrence of LGSOC after at least one prior systemic therapy for metastatic disease.\n5. Measurable disease according to RECIST v1.1.\n6. An Eastern Cooperative Group (ECOG) performance status ≤ 1.\n7. Adequate organ function.\n8. Adequate recovery from toxicities related to prior treatments.\n9. For patients with reproductive potential, a negative pregnancy test must be confirmed and agreement to use highly effective method of contraceptive.\n10. Willingness to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "Patients will be excluded from the study if they meet any of the following criteria:\n\n1. Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy.\n2. Co-existing high-grade serous ovarian cancer or mixed histology.\n3. Prior treatment with avutometinib, defactinib, or other FAK inhibitors.\n4. History of prior malignancy with recurrence <3 years from the time of enrollment.\n5. Major surgery within 4 weeks, minor surgery within 1 week, or palliative radiotherapy within 1 week of the first dose of study intervention.\n6. Symptomatic brain metastases requiring steroids or other interventions, known leptomeningeal metastases, or spinal cord compression.\n7. An active skin disorder that has required systemic therapy within one year of the first dose of study intervention.\n8. History of medically significant rhabdomyolysis.\n9. For subjects with prior MEK or RAF exposure, Grade 4 toxicity is deemed related to the MEK inhibitor.\n10. Symptomatic bowel obstruction within 3 months of the first dose of study intervention\n11. Concurrent ocular disorders.\n12. Concurrent heart disease or severe obstructive pulmonary disease.\n13. Active or past medical history of interstitial lung disease/pneumonitis, including drug-induced or radiation pneumonitis, pulmonary fibrosis, or adult respiratory distress syndrome (ARDS).\n14. Subjects with the inability to swallow oral medications.\n15. History of hypersensitivity to any of the active agents or ingredients of study intervention: peanut, soya, polyoxyl castor oil, etcetc.). Prior hypersensitivity to anthracyclines or anthracenediones if the use of pegylated liposomal doxorubicin (PLD) is planned.\n16. Pregnant or breastfeeding.\n17. Active, uncontrolled infection (bacterial, viral, or fungal) requiring systemic therapy.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Adequate organ function.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Adequate recovery from toxicities related to prior treatments.",
            "criterions": [
                {
                    "exact_snippets": "Adequate recovery from toxicities related to prior treatments",
                    "criterion": "recovery from prior treatment toxicities",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. For patients with reproductive potential, a negative pregnancy test must be confirmed and agreement to use highly effective method of contraceptive.",
            "criterions": [
                {
                    "exact_snippets": "patients with reproductive potential",
                    "criterion": "reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "a negative pregnancy test must be confirmed",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agreement to use highly effective method of contraceptive",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": "highly effective method"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. An Eastern Cooperative Group (ECOG) performance status ≤ 1.",
            "criterions": [
                {
                    "exact_snippets": "An Eastern Cooperative Group (ECOG) performance status ≤ 1.",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Histologically proven LGSOC (ovarian, fallopian, peritoneal)",
            "criterions": [
                {
                    "exact_snippets": "Histologically proven LGSOC (ovarian, fallopian, peritoneal)",
                    "criterion": "LGSOC (low-grade serous ovarian carcinoma)",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "primary site",
                            "expected_value": [
                                "ovarian",
                                "fallopian",
                                "peritoneal"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Progression or recurrence of LGSOC after at least one prior systemic therapy for metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "Progression or recurrence of LGSOC",
                    "criterion": "LGSOC disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "progression",
                                "recurrence"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least one prior systemic therapy for metastatic disease",
                    "criterion": "prior systemic therapy for metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "number of prior therapies",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Measurable disease according to RECIST v1.1.",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease according to RECIST v1.1.",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Documented mutational status of KRAS by a validated tumor-tissue based diagnostic test.",
            "criterions": [
                {
                    "exact_snippets": "Documented mutational status of KRAS",
                    "criterion": "KRAS mutational status",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "by a validated tumor-tissue based diagnostic test",
                    "criterion": "KRAS mutational status testing method",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": "validated tumor-tissue based diagnostic test"
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Willingness to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.",
            "criterions": [
                {
                    "exact_snippets": "Willingness to comply with the scheduled visits",
                    "criterion": "scheduled visits",
                    "requirements": [
                        {
                            "requirement_type": "willingness to comply",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willingness to comply with the ... treatment plan",
                    "criterion": "treatment plan",
                    "requirements": [
                        {
                            "requirement_type": "willingness to comply",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willingness to comply with the ... laboratory tests",
                    "criterion": "laboratory tests",
                    "requirements": [
                        {
                            "requirement_type": "willingness to comply",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Willingness to comply with the ... other study procedures",
                    "criterion": "other study procedures",
                    "requirements": [
                        {
                            "requirement_type": "willingness to comply",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "1. Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy.",
            "criterions": [
                {
                    "exact_snippets": "Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy.",
                    "criterion": "systemic anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks before first dose of study therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Subjects with the inability to swallow oral medications.",
            "criterions": [
                {
                    "exact_snippets": "inability to swallow oral medications",
                    "criterion": "ability to swallow oral medications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Concurrent heart disease or severe obstructive pulmonary disease.",
            "criterions": [
                {
                    "exact_snippets": "Concurrent heart disease",
                    "criterion": "heart disease",
                    "requirements": [
                        {
                            "requirement_type": "concurrence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe obstructive pulmonary disease",
                    "criterion": "obstructive pulmonary disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. An active skin disorder that has required systemic therapy within one year of the first dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "An active skin disorder that has required systemic therapy within one year of the first dose of study intervention.",
                    "criterion": "skin disorder",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "systemic therapy requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic therapy timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "year (from first dose of study intervention)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Major surgery within 4 weeks, minor surgery within 1 week, or palliative radiotherapy within 1 week of the first dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks ... of the first dose of study intervention.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event before first dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "minor surgery within 1 week ... of the first dose of study intervention.",
                    "criterion": "minor surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event before first dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "palliative radiotherapy within 1 week ... of the first dose of study intervention.",
                    "criterion": "palliative radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since event before first dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Concurrent ocular disorders.",
            "criterions": [
                {
                    "exact_snippets": "Concurrent ocular disorders",
                    "criterion": "ocular disorders",
                    "requirements": [
                        {
                            "requirement_type": "concurrence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Symptomatic brain metastases requiring steroids or other interventions, known leptomeningeal metastases, or spinal cord compression.",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic brain metastases requiring steroids or other interventions",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": [
                                "steroids",
                                "other interventions"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "known leptomeningeal metastases",
                    "criterion": "leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis status",
                            "expected_value": "known"
                        }
                    ]
                },
                {
                    "exact_snippets": "spinal cord compression",
                    "criterion": "spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Pregnant or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. History of medically significant rhabdomyolysis.",
            "criterions": [
                {
                    "exact_snippets": "History of medically significant rhabdomyolysis",
                    "criterion": "rhabdomyolysis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "medically significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "17. Active, uncontrolled infection (bacterial, viral, or fungal) requiring systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Active, uncontrolled infection (bacterial, viral, or fungal) requiring systemic therapy.",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "bacterial",
                                "viral",
                                "fungal"
                            ]
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "requiring systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History of prior malignancy with recurrence <3 years from the time of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "History of prior malignancy",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recurrence <3 years from the time of enrollment",
                    "criterion": "recurrence of prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time from enrollment to recurrence",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. History of hypersensitivity to any of the active agents or ingredients of study intervention: peanut, soya, polyoxyl castor oil, etcetc.). Prior hypersensitivity to anthracyclines or anthracenediones if the use of pegylated liposomal doxorubicin (PLD) is planned.",
            "criterions": [
                {
                    "exact_snippets": "History of hypersensitivity to any of the active agents or ingredients of study intervention: peanut, soya, polyoxyl castor oil, etcetc.",
                    "criterion": "hypersensitivity to study intervention ingredients",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ingredient_list",
                            "expected_value": [
                                "peanut",
                                "soya",
                                "polyoxyl castor oil"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior hypersensitivity to anthracyclines or anthracenediones if the use of pegylated liposomal doxorubicin (PLD) is planned.",
                    "criterion": "hypersensitivity to anthracyclines or anthracenediones",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "conditional_on_PLD_use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Co-existing high-grade serous ovarian cancer or mixed histology.",
            "criterions": [
                {
                    "exact_snippets": "Co-existing high-grade serous ovarian cancer",
                    "criterion": "high-grade serous ovarian cancer",
                    "requirements": [
                        {
                            "requirement_type": "co-existence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "mixed histology",
                    "criterion": "mixed histology",
                    "requirements": [
                        {
                            "requirement_type": "co-existence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Active or past medical history of interstitial lung disease/pneumonitis, including drug-induced or radiation pneumonitis, pulmonary fibrosis, or adult respiratory distress syndrome (ARDS).",
            "criterions": [
                {
                    "exact_snippets": "Active or past medical history of interstitial lung disease/pneumonitis",
                    "criterion": "interstitial lung disease/pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active or past medical history of ... drug-induced or radiation pneumonitis",
                    "criterion": "drug-induced or radiation pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active or past medical history of ... pulmonary fibrosis",
                    "criterion": "pulmonary fibrosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Active or past medical history of ... adult respiratory distress syndrome (ARDS)",
                    "criterion": "adult respiratory distress syndrome (ARDS)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Prior treatment with avutometinib, defactinib, or other FAK inhibitors.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with avutometinib",
                    "criterion": "prior treatment with avutometinib",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... defactinib",
                    "criterion": "prior treatment with defactinib",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with ... other FAK inhibitors",
                    "criterion": "prior treatment with other FAK inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Symptomatic bowel obstruction within 3 months of the first dose of study intervention",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic bowel obstruction within 3 months of the first dose of study intervention",
                    "criterion": "symptomatic bowel obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months from the first dose of study intervention"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. For subjects with prior MEK or RAF exposure, Grade 4 toxicity is deemed related to the MEK inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "prior MEK or RAF exposure",
                    "criterion": "prior MEK or RAF exposure",
                    "requirements": [
                        {
                            "requirement_type": "history of exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade 4 toxicity is deemed related to the MEK inhibitor",
                    "criterion": "Grade 4 toxicity related to MEK inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "toxicity grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 4,
                                "unit": "N/A"
                            }
                        },
                        {
                            "requirement_type": "causality",
                            "expected_value": "related to MEK inhibitor"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "3. Suitable for treatment with at least one of the Investigator's Choice of Treatments:pegylated liposomal doxorubicin, paclitaxel, letrozole, anastrozole.",
            "criterions": [
                {
                    "exact_snippets": "Suitable for treatment with at least one of the Investigator's Choice of Treatments: pegylated liposomal doxorubicin, paclitaxel, letrozole, anastrozole.",
                    "criterion": "suitability for treatment with at least one of the Investigator's Choice of Treatments",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment options",
                            "expected_value": [
                                "pegylated liposomal doxorubicin",
                                "paclitaxel",
                                "letrozole",
                                "anastrozole"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Patients may be eligible for inclusion in the study if they meet the following criteria:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "Patients will be excluded from the study if they meet any of the following criteria:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}